Preclinical models for evaluating psychedelics in the treatment of major depressive disorder DOI Creative Commons
Laith Alexander, David J. Anderson, Luke Baxter

и другие.

British Journal of Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 28, 2024

Psychedelic drugs have seen a resurgence in interest as next generation of psychiatric medicines with potential rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie effects psychedelics are poorly understood. For example, key questions such whether antidepressant and psychedelic involve related or independent unresolved. Preclinical studies relevant animal models to understanding pharmacology translating these findings explain efficacy safety patients. Understanding action associated behavioural can also support identification novel drug targets more effective treatments. Here we review approaches currently used quantify drugs. We discuss conceptual methodological issues, importance using clinically doses need consider possible sex differences preclinical studies.

Язык: Английский

Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications DOI Creative Commons
Francesco Weiss, Anna Magnesa,

Matteo Gambini

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(2), С. 117 - 117

Опубликована: Янв. 25, 2025

Background: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still lively controversy in the medical community regards rationale of their employment, specifically indications potential dangers. Methods: A comprehensive literature search on “MEDLINE/PubMed” “Web Science” was performed from inception to 26 June 2024, cross-checking obtained references. We included all studies, i.e., both clinical preclinical, that supplied original data. Results: initially total 1083 entries, 813 MEDLINE/PubMed 270 Web Science. After duplicate elimination, 903 underwent systematic selection. Primary abstract screening yielded 572 candidates eligibility assessment excluded 331 entries formal grounds. Eligibility led exclusion 501 titles. Finally, 70 articles were this review. Discussion: Preclinical evidence genetic expression, histology behavioral studies soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, seems be inferentially agreement preclinical findings. it unclear whether “neuroplastic boost” induced by classic might dissociable psychodysleptic effects, thereby reducing psychopathological hazards implied these compounds. Moreover, fact so-called “relaxation priors” should unconditionally beneficial appears debatable, further research clarify possible contraindications psychedelic psychoplastogens within precision medicine perspective.

Язык: Английский

Процитировано

5

Examining memory reconsolidation as a mechanism of nitrous oxide’s antidepressant action DOI Creative Commons

Ella Williams,

Uršulė Taujanskaitė, Sunjeev K. Kamboj

и другие.

Neuropsychopharmacology, Год журнала: 2025, Номер 50(4), С. 609 - 617

Опубликована: Янв. 17, 2025

There is an ongoing need to identify novel pharmacological agents for the effective treatment of depression. One emerging candidate, which has demonstrated rapid-acting antidepressant effects in treatment-resistant groups, nitrous oxide (N2O)-a gas commonly used sedation and pain management clinical settings with a range effects, including antagonism NMDA glutamate receptors. A growing body evidence suggests that subanaesthetic doses N2O (50%) can interfere reconsolidation maladaptive memories healthy participants across disorders. Negative biases memory play key role onset, maintenance, recurrence depressive episodes, disruption affective one plausible mechanism through exerts its therapeutic effects. Understanding N2O's mechanisms action may facilitate future development In this narrative review, we introduce supporting profile evaluate use compared other treatments. With focus on specific processes are thought be disrupted depression, consider propose memory-based action.

Язык: Английский

Процитировано

0

Delivering a new generation of translational animal models for depression research DOI
Emma Robinson

Behavioural Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Март 6, 2025

Early animal models of depression focused on developing methods that could predict treatment efficacy and were validated based pharmacological responses to known antidepressants. As our understanding major depressive disorder (MDD) the pharmacology antidepressants progressed, so did need for better models. This was met with development new disease models, such as chronic mild stress model, behavioural readouts sucrose preference test, which more closely aligned risk factors symptoms seen in patients. These approaches have supported huge advances how affects brain impacts reward-related behaviours. However, there remain significant challenges when trying model complex psychiatric disorders non-human animals. In this perspective article, a brief history associated is discussed specific reference important contributions from Paul Willner. The main discussion then focuses translational validity may support delivering objective. illustrated example affective bias test reward learning assays, been developed recapitulate animals neuropsychological impairments observed MDD modulation by

Язык: Английский

Процитировано

0

Cognitive and affective models of psychedelics in rodents DOI
David J. Anderson, Emma Robinson

International review of neurobiology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Investigating the effects of different herbal preparations, 5-hydroxytryptophan and involuntary exercise on affective bias modification in male Lister Hooded rats DOI
Justyna K. Hinchcliffe, Sarah A. Stuart, Emma Robinson

и другие.

Behavioural Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Mood disorders are a prevalent global health concern with natural products, including herbal supplements, an increasingly popular choice as alternative or complementary therapy. Despite their widespread use, few studies have tested the clinical efficacy of products explored underlying mechanisms in animal models. Modification affective biases has been linked to mood humans and models may provide insights into potential antidepressant effects. In this study, we used translational rodent model bias modification investigate effects five commonly supplements: Hypericum perforatum, that is, St. John's Wort (SJW), Mucuna pruriens, Rhodiola rosea root extract, Valerian extract 5-hydroxytryptophan. Exercise is also thought improve disorders, but reveal mixed results therefore effect involuntary exercise on biases. separate experiments, male Lister Hooded rats were acutely treated SJW, 5-hydroxytryptophan, underwent manipulation. Our showed significant positive following treatment whilst induced negative rats. No found other acute treatments. These data suggest SJW similar terms conventional antidepressants. The observed suggests animals experience state exercise-based therapy be less effective if patient perceives involuntary.

Язык: Английский

Процитировано

0

The Affective Bias Test and Reward Learning Assay: Neuropsychological Models for Depression Research and Investigating Antidepressant Treatments in Rodents DOI Creative Commons
Justyna K. Hinchcliffe, Emma Robinson

Current Protocols, Год журнала: 2024, Номер 4(6)

Опубликована: Июнь 1, 2024

The Affective Bias Test (ABT) quantifies acute changes in affective state based on the biases they generate an associative reward learning task. Reward Learning Assay (RLA) provides a control assay for ABT and reward-induced generated this model are sensitive to core state. Both tasks involve training animals associate specific digging substrate with food reward. Animals learn discriminate between two substrates placed ceramic bowls, one rewarded unrewarded. In ABT, animal learns independent substrate-reward associations fixed value following either or drug manipulation, under conditions. quantified choice test where exhibit bias (make more choices) of which is specifically related at time learning. used investigate during as well modulation associated past experiences. RLA follows similar protocol, but remains same throughout by pairing higher determine if treatments affect memory retrieval generally. Studies depression models environmental enrichment suggest that Each task offers different insights into processing mechanisms may help improve translational validity studies benefit pre-clinical development. © 2024 Authors. Current Protocols published Wiley Periodicals LLC. Basic Protocol 1: Bowl discrimination 2: 3: - new 4:

Язык: Английский

Процитировано

3

Ketamin und Esketamin DOI
Cornelius Schüle,

Gabi Koller,

Uwe Herwig

и другие.

Nervenheilkunde, Год журнала: 2024, Номер 43(06), С. 366 - 373

Опубликована: Июнь 1, 2024

ZUSAMMENFASSUNG Ketamin blickt bereits auf eine längere Geschichte der Anwendung in Psychiatrie zurück. Insbesondere ist es den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden mit dem Enantiomer Esketamin Deutschland für diese Indikation zugelassen. Hier wird vor allem als pharmakologische Intervention genutzt. kann zudem atypisches Psychedelikum oder Dissoziativum bezeichnet werden, da die Wirkung einer charakteristischen qualitativen Bewusstseinsänderung einhergeht. Insofern gibt Ansätze, psychophänomenologische therapeutisch im Sinne ketaminaugmentierten Psychotherapie zu nutzen. Dies aber Studienlage nicht untermauert. Im Artikel werden zunächst Aspekte vorgestellt, dann aktuelle klinisch-psychiatrische Anwendungen letztlich Überlegung diskutiert, erlebte Bewusstseinsinhalte psychotherapeutisch einzubringen.

Процитировано

1

Effects of psilocybin on uncertain punishment learning DOI
David S. Jacobs,

Alina Bogachuk,

Chloé L. Le Moing

и другие.

Neurobiology of Learning and Memory, Год журнала: 2024, Номер 213, С. 107954 - 107954

Опубликована: Июнь 22, 2024

Язык: Английский

Процитировано

1

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder DOI Creative Commons
Laith Alexander, David J. Anderson, Luke Baxter

и другие.

British Journal of Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 28, 2024

Psychedelic drugs have seen a resurgence in interest as next generation of psychiatric medicines with potential rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie effects psychedelics are poorly understood. For example, key questions such whether antidepressant and psychedelic involve related or independent unresolved. Preclinical studies relevant animal models to understanding pharmacology translating these findings explain efficacy safety patients. Understanding action associated behavioural can also support identification novel drug targets more effective treatments. Here we review approaches currently used quantify drugs. We discuss conceptual methodological issues, importance using clinically doses need consider possible sex differences preclinical studies.

Язык: Английский

Процитировано

1